Palisade Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Palisade Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-680,422	Closed	-$9.55M	–	454
2017 Q1	$9.55M	Buy	680,422 +25,110	+4%	+$411K	0.37%	84
2016 Q4	$12.3M	Sell	655,312 -13,085	-2%	-$222K	0.46%	68
2016 Q3	$11M	Sell	668,397 -5,232	-0.8%	-$77.5K	0.39%	75
2016 Q2	$9.05M	Sell	673,629 -30,721	-4%	-$448K	0.33%	90
2016 Q1	$10.8M	Buy	704,350 +147,102	+26%	+$2.31M	0.35%	88
2015 Q4	$11.1M	Buy	557,248 +172,191	+45%	+$3.27M	0.36%	86
2015 Q3	$6.71M	Buy	385,057 +154,822	+67%	+$3.15M	0.2%	183
2015 Q2	$4.66M	Buy	+230,235	New	+$4.44M	0.12%	276

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Palisade Capital Management's AMRI Position: Q2 2017 in Review

Palisade Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 680,422 shares — an estimated $9.55M sold.

Palisade Capital Management first reported a position in AMRI in Q2 2015 and held it in 8 quarters. The position peaked at $12.3M in Q4 2016. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

Palisade Capital Management reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
Palisade Capital Management sold 680,422 Albany Molecular Research Inc shares in Q2 2017, an estimated $9.55M.
Palisade Capital Management first reported a position in Albany Molecular Research Inc in Q2 2015 and held it in 8 quarters.
Palisade Capital Management's Albany Molecular Research Inc position peaked at $12.3M in Q4 2016.
136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Palisade Capital Management's 13F filing for Q2 2017, filed 1 Aug 2017.